For Parts B, C, D and E, scans will be collected centrally to be reviewed in real time by BICR. Abbreviations: ADA = anti-drug antibody; BICR = blinded i ndependent central review; DLT = dose limiting toxicity; DOR = duration of response; mDOR = median duration of response; ORR = objective response rate; PK = pharmacoki netics; RECIST = Res ponse Evaluation Criteria In Solid Tumors; TIL = tumor-infiltrating lymphocytes. Revised Protocol No.: 04 Date: 31-May-2019 50 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS 5 STUDY DESIGN Figure 5-1: Study Design Schematic * Note: Arms B2 and C2 will enro ll only if additional safety, PK, and PD data are required to inform dose expansion decisions.